Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.93 | 1.93 |
NAV | ₹426.54 | ₹38.47 |
Fund Started | 04 Jun 1999 | 12 Nov 2018 |
Fund Size | ₹3689.28 Cr | ₹2961.36 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 0.50% if redeemed within 1 month. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 19.31% | 16.42% |
3 Year | 29.09% | 26.26% |
5 Year | 24.17% | 23.34% |
1 Year
3 Year
5 Year
Equity | 96.09% | 99.27% |
Cash | 3.83% | 0.73% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.73% |
Divi's Laboratories Ltd. | 7.39% |
Max Healthcare Institute Ltd. | 6.40% |
Lonza Group Ag | 4.81% |
Cipla Ltd. | 4.77% |
Lupin Ltd. | 4.46% |
Mankind Pharma Ltd. | 3.75% |
Krishna Institute of Medical Sciences Ltd | 3.34% |
Fortis Healthcare Ltd. | 3.22% |
Acutaas Chemicals Ltd. | 3.19% |
Name | Assets |
---|---|
Cohance Lifesciences Ltd. | 9.72% |
Sun Pharmaceutical Industries Ltd. | 9.66% |
Cipla Ltd. | 9.53% |
Ipca Laboratories Ltd. | 8.16% |
Globus Medical Inc | 5.63% |
Apollo Hospitals Enterprise Ltd. | 4.67% |
Laurus Labs Ltd. | 4.60% |
Gland Pharma Ltd. | 4.43% |
Alembic Pharmaceuticals Ltd. | 4.29% |
Sai Life Sciences Ltd. | 3.82% |
Name | Tanmaya Desai | Jay Kothari |
Start Date | 27 Jun 2011 | 16 Mar 2018 |
Name
Start Date
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 04 Jun 1999 | 12 Nov 2018 |
Description
Launch Date